Duchenne Muscular Dystrophy (DMD) is a genetic and progressive neuromuscular disorder that primarily affects boys. It is one of the most common and severe forms of muscular dystrophy. DMD is caused by a mutation in the gene that encodes for a protein called dystrophin, which is essential for maintaining the structure and function of muscle fibers.
Established in 1937, the company has its headquarters in Waltham, Massachusetts, United States. Richard Scott Perkin and Charles Elmer are the founding fathers of this company. It predominantly operates in the field of diagnostics and life sciences.
PerkinElmer role in the Duchenne Muscular Dystrophy diagnostic vertical involves providing tools, technologies, and expertise that support genetic testing, research, diagnostics development, and patient care in the context of DMD. These contributions are crucial for improving the understanding of the disease and enhancing the quality of life for individuals affected by DMD.
The company was established in 1896 and is a subsidiary of the international conglomerate Koninklijke Philips N.V. It provides a wide range of medical devices, services, and technologies for various healthcare applications, including diagnostic imaging, patient monitoring, and healthcare informatics.
With context to DMD, it offers equipment like magnetic resonance imaging (MRI) and ultrasound machines that can be used in the diagnosis and monitoring of DMD, particularly to assess muscle health and track disease progression. Philips Healthcare also offers solutions for home-based healthcare and rehabilitation. These can be important for DMD patients to manage their condition, receive physiotherapy, and maintain a better quality of life.
This French pharma company was established in 1973. Its headquarters are situated in Paris, France. It is involved in the development and manufacturing of a wide range of pharmaceutical products.
Sanofi conducts research and development activities focused on rare diseases, including DMD. The company has been involved in the exploration of potential therapies, including gene-based treatments, to address the underlying causes of DMD. It has widespread expertise in gene therapy and rare diseases, which are particularly relevant to DMD.
Founded on December 27th, 2000, the company has its headquarters in Brentford, United Kingdom. It is one of the leading pharma companies in the world.
GSK conducts research and development activities with a focus on rare diseases, including DMD. The company is involved in exploring potential therapies and treatment approaches, such as gene-based therapies, to address the underlying causes of DMD.
Milan Puskar and Don Panoz established this pharma company in 1961. Its headquarters are located in Canonsburg, Pennsylvania, United States.
Mylan focuses in providing generic and specialty pharmaceuticals, as well as over-the-counter healthcare products. While Mylan is primarily known for its wide range of generic and biosimilar medicines, it has been involved in the treatment vertical for rare diseases, including Duchenne Muscular Dystrophy (DMD).
In the field of Duchenne Muscular Dystrophy (DMD) research, diagnosis, and treatment, several companies play significant roles. These companies contribute to various aspects of DMD, from research and development to patient care and advocacy. Sarepta Therapeutics is at the forefront of DMD research, known for its groundbreaking work in exon-skipping therapies. PTC Therapeutics focuses on precision medicine for rare diseases, targeting the specific genetic mutations causing DMD. PerkinElmer offers crucial diagnostic tools and technologies, aiding in early diagnosis and research. Philips Healthcare provides medical imaging and informatics solutions to assist in DMD diagnosis and monitoring. GlaxoSmithKline (GSK) conducts research and development, with a focus on gene therapy, while Mylan N.V., now part of Viatris, is involved in research and initiatives to improve patient access to DMD treatments. These companies, among others, are dedicated to advancing our understanding and treatment of DMD, offering hope and support to those affected by this challenging condition. Staying updated with the latest developments and advancements in DMD research and treatment is crucial by referring to official sources and recent news in the field.